Investigating excessive supraventricular activity and its link to atrial fibrillation
Detection of Atrial Fibrillation in Patients With Excessive Supraventricular Activity
This study is testing whether people with extra heartbeats detected by a monitor should get more screening to find out if they have undiagnosed atrial fibrillation or flutter.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 70 Years to 89 Years |
| Sex | All |
| Sponsor | Karolinska Institutet Academic / other |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT04593498 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine whether individuals with excessive supraventricular ectopic activity (ESVEA) detected through Holter monitoring should undergo prolonged screening with an Event loop recorder to identify undiagnosed atrial fibrillation or flutter. The study will compare ESVEA patients with a matched control group, assessing various biomarkers, echocardiographic data, and cardiovascular health over a period of 21 months. Participants will also complete questionnaires and have blood samples collected for further analysis of potential atrial fibrillation biomarkers.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 70 to 89 with excessive supraventricular ectopic activity as identified on Holter recordings.
Not a fit: Patients under 70 or over 89 years old, those with existing atrial fibrillation or flutter, or those on lifelong anticoagulant therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and management of atrial fibrillation, potentially reducing the risk of stroke and other complications for patients.
How similar studies have performed: Other studies have shown promising results in identifying atrial fibrillation through similar monitoring techniques, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats on a Holter recording. Exclusion Criteria: Age \< 70 years, \>89 years Atrial fibrillation / flutter Lifelong treatment with oral anticoagulant Patients with implantable cardiac device Congestive heart failure (CHF) with Ejection fraction (EF) ≤ 30% Severe valvular heart disease
Where this trial is running
Stockholm
- Danderyd Hospital — Stockholm, Sweden (Recruiting)
Study contacts
- Study coordinator: Johan Engdahl
- Email: johan.engdahl@regionstockholm.se
- Phone: 0046812358242
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.